Levalbuterol
Product Images NDC 68071-2340

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Levalbuterol (NDC 68071-2340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2340 5)

Label for Levalbuterol 1.25 mg/3 mL U-D Vials from NuCare Pharmaceuticals, Inc. The package contains 25 vials of 3 mL each. The label includes the NDC number 68071-2340-5, manufacturer and packager information Sun Pharmaceutical Medicare Limited, Hallol, Gujarat, India, and cautionary text advising use only as directed by a physician and to keep out of reach of children.*

FDA Label Image

Levalbuterol-chemical-structure (Levalbuterol Chemical Structure)

Chemical structure of Levalbuterol hydrochloride, showing the arrangement of hydroxyl groups, an amine group, a substituted propanol chain, and a benzene ring.*

FDA Label Image

Levalbuterol-figure-1 (Levalbuterol Figure 1)

A line graph showing the mean percent change from baseline FEV1 on Day 1 in adults and adolescents aged 12 years and older. The x-axis represents time in hours from 0 to 8, while the y-axis shows the mean change in FEV1 percentage ranging from -5 to 45%. Four lines represent groups receiving Levalbuterol 1.25, Levalbuterol 0.63, Racemic 2.5, and placebo, respectively, comparing their lung function improvement over time.*

FDA Label Image

Levalbuterol-figure-2 (Levalbuterol Figure 2)

A line graph titled 'Mean Percent Change from Baseline FEV1 on Day 29, Adults and Adolescents ≥12 years old.' It shows mean change in FEV1 (%) on the vertical axis over time in hours on the horizontal axis (0 to 8 hours). Four groups are depicted: Lev 1.25, Lev 0.63, Rac 2.5, and PBO, each represented by different symbols. Lev 1.25 shows the highest peak increase in FEV1, while PBO remains lowest throughout. A horizontal dashed line marks 15% mean change threshold.*

FDA Label Image

Levalbuterol-figure-3 (Levalbuterol Figure 3)

A line graph showing mean percent change from baseline FEV1 on Day 1 for children aged 6 to 11 years over a 4-hour period. The graph compares five groups: Levalbuterol 0.63, Levalbuterol 0.31, Racemic albuterol 2.5, Racemic albuterol 1.25, and placebo, with FEV1 change (%) on the y-axis and time in hours on the x-axis. Each group is represented by distinct markers and sample sizes.*

FDA Label Image

Levalbuterol-figure-4 (Levalbuterol Figure 4)

Line graph titled 'Mean Percent Change from Baseline FEV1 on Day 21, Children 6 to 11 Years of Age' showing mean change in FEV1 (%) over time (hours) for different treatments: Levalbuterol at two dosages (0.63, 0.31), Racemic albuterol (2.5, 1.25), and placebo. The graph tracks five groups with data points from 0 to 4 hours, illustrating changes in mean FEV1 percentage with a legend specifying sample sizes for each group.*

FDA Label Image

A (Levalbuterol Figure A)

An illustration labeled Figure A depicting a top-down schematic view of a nasal spray bottle with a cap and nozzle. The drawing highlights the components and structure of the spray container, likely related to the Levalbuterol product.*

FDA Label Image

B (Levalbuterol Figure B)

Illustration labeled Figure B showing the top edge of a packaging component with two notches indicated on either side. The image likely depicts a detail of the packaging design related to the Levalbuterol product from NuCare Pharmaceuticals, Inc.*

FDA Label Image

C (Levalbuterol Figure C)

An instructional line drawing labeled 'Figure C' showing two hands handling a single-dose vial or ampule with a break-off top, illustrating how to hold it for opening. No text other than the figure label is visible.*

FDA Label Image

D (Levalbuterol Figure D)

An instructional diagram labeled Figure D showing a hand inserting a vial into the reservoir of a device. The vial and reservoir are labeled to indicate how the vial fits into the reservoir component.*

FDA Label Image

E (Levalbuterol Figure E1 E2)

An illustration diagram showing two labeled assemblies for inhalation therapy. The left diagram labels a mouthpiece attached to a reservoir chamber. The right diagram shows a face mask connected to a similar reservoir chamber. Both reservoirs appear cylindrical with a side nozzle and a top cap.*

FDA Label Image

F (Levalbuterol Figure F)

An illustration showing a compressor device with a labeled connection point where nebulizer tubing is attached. The diagram is labeled as Figure F and highlights the connection between the nebulizer tubing and the compressor unit.*

FDA Label Image

G (Levalbuterol Figure G1 G2)

Illustration showing proper use of a Levalbuterol inhalation device with labeled parts. Figure G.1 demonstrates using the mouthpiece with the reservoir held in the hand, while Figure G.2 shows using the face mask attached to the reservoir. Both diagrams highlight the mouthpiece or face mask and the reservoir component of the device.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.